Lorenc Tomasz, Chrzanowski Julian, Olejarz Wioletta
Ist Department of Clinical Radiology, Medical University of Warsaw, 5 Chalubinskiego Street, 02-004 Warsaw, Poland.
Department of Biochemistry and Pharmacogenomics, Faculty of Pharmacy, Medical University of Warsaw, 02-097 Warsaw, Poland.
Cancers (Basel). 2020 Nov 16;12(11):3386. doi: 10.3390/cancers12113386.
An appropriate combination of biomarkers and imaging technologies will become standard practice in the future. Because the incidence of and mortality from cancers is rising, the further study of new approaches for the early detection and precise characterization of tumors is essential. Extracellular vesicles (EVs), including exosomes, prove to have great potential when it comes to diagnosis and targeted therapy. Due to their natural ability to pass through biological barriers, depending on their origin, EVs can accumulate at defined sites, including tumors, preferentially. This manuscript discusses the difficulties and simplicities of processing cell-derived materials, packaging diverse groups of agents in EVs, and activating the biological complex. Developing exosome-based diagnostic techniques to detect disease precisely and early as well as treat disease marks a new era of personalized radiology and nuclear medicine. As circulating drug delivery vehicles for novel therapeutic modalities, EVs offer a new platform for cancer theranostic.
生物标志物和成像技术的适当结合将在未来成为标准做法。由于癌症的发病率和死亡率正在上升,进一步研究肿瘤早期检测和精确表征的新方法至关重要。细胞外囊泡(EVs),包括外泌体,在诊断和靶向治疗方面具有巨大潜力。由于其天然能够穿过生物屏障,根据其来源,EVs可以优先在特定部位,包括肿瘤部位积聚。本文讨论了处理细胞衍生材料、将不同类型的试剂包装到EVs中以及激活生物复合物的困难和简便之处。开发基于外泌体的诊断技术以早期精确检测疾病以及治疗疾病标志着个性化放射学和核医学的新时代。作为新型治疗方式的循环药物递送载体,EVs为癌症诊疗提供了一个新平台。